Plasma proteomics identifies insulin resistance signatures predictive of cardiometabolic disease risk
Year: 2026
Type: article
Abstract: Insulin resistance drives cardiometabolic disease, yet its molecular signatures and tissue origins remain incompletely characterized. Here we define a circulating protein signature that enables scalable assessment of insulin sensitivity. We applied multiworkflow proteomics to plasma from 161 individuals spanning the insulin sensitivity spectrum defined by the hyperinsulinaemic–euglycaemic clamp and identified 488 proteins associated with insulin sensitivity, capturing contributions from liver, adipose tissue and immune cells. A subset of these proteins shifted towards a more insulin-sensitive profile following an exercise intervention in men. We further developed a model combining 13 proteins, including IGFBP1, LEP, GDF15, PON3 and LDLR, with clinical variables (sex, HbA1c and the triglyceride-to-high-density lipoprotein cholesterol ratio) to predict insulin sensitivity ( R 2 = 0.67). In ~20,000 UK Biobank participants, the model outperformed the triglyceride-to-high-density lipoprotein cholesterol ratio in predicting type 2 diabetes (concordance index, 0.86 versus 0.74) and, unlike HbA1c, predicted hepatic, renal, cardiovascular and respiratory disease. In an independent cohort of 1,700 individuals, the model also showed greater predictive utility than fasting insulin resistance indices, including the homeostatic model assessment of insulin resistance. Together, these findings establish a tissue-resolved plasma proteomic framework for characterizing insulin resistance and provide a scalable approach to precision cardiometabolic risk stratification.
Source: Nature Metabolism
Authors: Jeppe Kjærgaard(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft), Nigel Kurgan(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft), Justus F. Gräf(Data curation, Formal analysis), Naixin Zhang(Formal analysis, Investigation), Zhe Wang(Formal analysis, Investigation), Mafalda Da Cruz Custódio(Formal analysis), Farina Schlabs(Investigation), Paola Pisano(Data curation, Investigation, Methodology), Lisa Ottander(Investigation), Maria Houborg Petersen(Investigation), Martin Eisemann de Almeida(Investigation), Jacob Stidsen(Investigation), Jordi Merino(Funding acquisition, Resources), Tuomas O. Kilpeläinen(Funding acquisition, Resources), Niels Ørtenblad(Investigation, Resources), Mikael Rydén(Investigation, Resources), Simon Rasmussen(Resources), Anna Krook(Funding acquisition, Resources), Marta Guasch-Ferré(Funding acquisition, Resources), Ruth J. F. Loos(Funding acquisition, Resources), Roelof A. J. Smit(Data curation, Formal analysis), Kurt Højlund(Funding acquisition, Investigation, Resources), Juleen R. Zierath(Funding acquisition, Resources), Michael Wierer(Data curation, Investigation, Methodology, Resources), Atul S. Deshmukh(Conceptualization, Funding acquisition, Methodology, Resources, Supervision, Writing – original draft)
Institutions: Broad Institute, University of Copenhagen, Novo Nordisk Foundation Center for Basic Metabolic Research, Massachusetts Institute of Technology, University of Alabama at Birmingham, Icahn School of Medicine at Mount Sinai, Odense University Hospital, University of Southern Denmark, University of British Columbia, Karolinska University Hospital, Karolinska Institutet, Steno Diabetes Center Copenhagen, Harvard University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: insulin resistance, plasma proteomics, cardiometabolic risk, insulin sensitivity, type 2 diabetes prediction, IGFBP-1, LEP, GDF15, PON3, LDL receptor, exercise intervention, hyperinsulinemic-euglycemic clamp, HbA1c, triglyceride to HDL cholesterol ratio, liver, adipose tissue, immune cells
Open Access status: hybrid
Estimated APC paid: $12,690
Funders: Hjerteforeningen, Lundbeckfonden, Karolinska Institutet, Knut och Alice Wallenbergs Stiftelse, Novo Nordisk, Odense Universitetshospital, Vetenskapsrådet, Syddansk Universitet, Copenhagen Graduate School for Nanoscience and Nanotechnology, Faculty of Health and Medical Sciences, University of Western Australia, Novo Nordisk Fonden, Novo Nordisk Foundation Center for Basic Metabolic Research, H. Lundbeck A/S, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet, National Heart, Lung, and Blood Institute
Awards: G166378266, G1713276838, G1737745227, G186104510, G1876651919, G2450079431, G2608456928, G3416057414, G4105288177, G4119608294, G4215173622, G4230908485, G4504918650, G4564598272, G5084703174, G5100435507, G5230343151, G5295594445, G5502767821, G553931797, Epigenomic Control and the Molecular Resolution of Insulin Resistance in Diabetes, G6244141529, Regulation of skeletal muscle health with respect to metabolism and insulin sensitivity; role of non-coding RNA, G8221995800, G8351935874, G8547927097, Genotypic and phenotypic approaches to subtype individuals with coronary heart disease, G912250276, G95156616
OpenAlex ID: W7125178676
